tiprankstipranks
Advertisement
Advertisement
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
PremiumThe FlyPsychedelic: Enveric, NRx, Bright Minds report quarterly earnings
1M ago
Compass Pathways price target raised to $20 from $12 at Maxim
Premium
The Fly
Compass Pathways price target raised to $20 from $12 at Maxim
1M ago
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
Premium
The Fly
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
1M ago
Psychedelic: FDA awards Compass Pathways priority review voucher
PremiumThe FlyPsychedelic: FDA awards Compass Pathways priority review voucher
2M ago
Analyst Reiterates Buy on COMP360 Amid Accelerated Regulatory Momentum, Maintains $70 Price Target
Premium
Ratings
Analyst Reiterates Buy on COMP360 Amid Accelerated Regulatory Momentum, Maintains $70 Price Target
2M ago
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
Premium
The Fly
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100